Structure-based approaches to drug discovery against tuberculosis

Area of Science:

• Structural biology
• Microbiology
• Drug discovery

Background:

• Tuberculosis (TB) remains a global health emergency, exacerbated by multidrug-resistant strains and immunocompromised populations.
• The availability of the Mycobacterium tuberculosis genome offers opportunities for targeted drug development, yet progress has been slow due to limited industry interest.
• Elucidating molecular structures of potential drug targets is crucial for advancing TB drug discovery.

Purpose of the Study:

• To present the approach and achievements of the X-MTB consortium in determining Mycobacterium tuberculosis target structures.
• To summarize recent highlights of potential drug targets involved in key metabolic pathways.
• To underscore the role of structural genomics in facilitating international, industry-academic collaborations for TB drug discovery.

Main Methods:

• Determination of molecular structures of potential drug targets from the Mycobacterium tuberculosis proteome.
• Focus on targets involved in lipid metabolism, protein phosphorylation/dephosphorylation, and amino acid biosynthesis.
• Leveraging achievements from structural genomics consortia.

Main Results:

• Approximately 200 unique target structures from Mycobacterium tuberculosis have been determined, representing about 5% of its proteome.
• Identified key potential drug targets in lipid metabolism, protein phosphorylation/dephosphorylation, and amino acid biosynthesis.
• Established a framework supporting international, structure-based drug discovery efforts.

Conclusions:

• Structural genomics provides a robust foundation for coordinated international TB drug discovery programs.
• Collaboration between industrial enterprises and academic research is essential for overcoming TB.
• Future efforts should expand to include target complexes, not solely single targets, to enhance drug discovery pipelines.